Published in J Heart Lung Transplant on April 01, 2006
Inhibiting CXCL12 blocks fibrocyte migration and differentiation and attenuates bronchiolitis obliterans in a murine heterotopic tracheal transplant model. J Thorac Cardiovasc Surg (2012) 0.93
Rapamycin blocks fibrocyte migration and attenuates bronchiolitis obliterans in a murine model. Ann Thorac Surg (2013) 0.86
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet (2009) 0.83
Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis. Paediatr Drugs (2017) 0.75
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant (2002) 5.49
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med (2015) 3.25
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J (2006) 2.61
Single-centre experience of donation after cardiac death. Med J Aust (2012) 2.60
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant (2004) 2.09
Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system. J Heart Lung Transplant (2007) 1.88
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant (2008) 1.54
Increased resource use in lung transplant admissions in the lung allocation score era. Am J Respir Crit Care Med (2015) 1.45
Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation (2004) 1.45
Predictors of independent lung ventilation: an analysis of 170 single-lung transplantations. J Thorac Cardiovasc Surg (2007) 1.42
Feasibility and utility of a lung donor score: correlation with early post-transplant outcomes. Ann Thorac Surg (2007) 1.40
Unilateral radiographic abnormalities after bilateral lung transplantation: exclusion from the definition of primary graft dysfunction? J Thorac Cardiovasc Surg (2006) 1.39
Robustness of methods for blinded sample size re-estimation with overdispersed count data. Stat Med (2013) 1.39
Unexpected donor pulmonary embolism affects early outcomes after lung transplantation: a major mechanism of primary graft failure? J Thorac Cardiovasc Surg (2005) 1.39
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol (2002) 1.33
Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med (2010) 1.17
A review of lung transplant donor acceptability criteria. J Heart Lung Transplant (2003) 1.16
The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci (2009) 1.15
Clinical application of airway bypass with paclitaxel-eluting stents: early results. J Thorac Cardiovasc Surg (2007) 1.11
Acute fibrinoid organizing pneumonia after lung transplantation. Am J Respir Crit Care Med (2013) 1.10
Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. J Clin Pharmacol (2002) 1.10
Lung transplantation: does age make a difference? Med J Aust (2007) 1.07
Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin (2007) 1.06
Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. J Heart Lung Transplant (2005) 1.02
Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos (2007) 0.99
Strategies to optimize the use of currently available lung donors. J Heart Lung Transplant (2004) 0.99
Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit (2004) 0.98
Obliterative bronchiolitis or chronic lung allograft rejection: a basic science review. J Heart Lung Transplant (2005) 0.96
Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. COPD (2012) 0.95
Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant (2008) 0.95
A donor history of smoking affects early but not late outcome in lung transplantation. Transplantation (2004) 0.89
Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation (2005) 0.88
Pneumonia severity index in the immunocompromised. Can Respir J (2006) 0.88
Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler (2012) 0.88
Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg (2006) 0.87
Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler (2011) 0.87
Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. Ann Thorac Surg (2011) 0.85
Airway vascular changes after lung transplant: potential contribution to the pathophysiology of bronchiolitis obliterans syndrome. J Heart Lung Transplant (2005) 0.85
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study. Pediatr Dermatol (2005) 0.84
A practical guide to Bayesian group sequential designs. Pharm Stat (2013) 0.83
Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. Am J Med (2004) 0.83
Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Stat Med (2010) 0.83
Genetics of cystic fibrosis. Semin Respir Crit Care Med (2009) 0.83
Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation. Ann Thorac Surg (2006) 0.83
High donor age, low donor oxygenation, and high recipient inotrope requirements predict early graft dysfunction in lung transplant recipients. J Heart Lung Transplant (2005) 0.82
Using historical control information for the design and analysis of clinical trials with overdispersed count data. Stat Med (2013) 0.81
Preliminary report of the safety and efficacy of hyperbaric oxygen therapy for specific complications of lung transplantation. J Heart Lung Transplant (2006) 0.80
The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. Br J Clin Pharmacol (2009) 0.80
Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents (2004) 0.80
Early changes in basement membrane thickness in airway walls post-lung transplantation. J Heart Lung Transplant (2005) 0.80
Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. Antimicrob Agents Chemother (2013) 0.79
Evaluation of the oxygenation ratio in the definition of early graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg (2005) 0.79
Bronchiolitis obliterans syndrome leads to a functional deterioration of the acinus post lung transplant. Thorax (2013) 0.79
Impaired muscle Ca2+ and K+ regulation contribute to poor exercise performance post-lung transplantation. J Appl Physiol (1985) (2003) 0.79
Calcineurin inhibitor-related cholestasis complicating lung transplantation. Ann Thorac Surg (2010) 0.78
Buying time: The use of extracorporeal membrane oxygenation as a bridge to lung transplantation in pediatric patients. Pediatr Transplant (2013) 0.78
Pectus excavatum with inspiratory inferior vena cava compression: a new presentation of pulsus paradoxus. Am J Med Sci (2005) 0.78
Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant (2005) 0.78
The pulmonary effects of long-term exposure to aerosol pentamidine: a 5-year surveillance study in HIV-infected patients. Chest (2003) 0.78
Predictors of a more favourable response to combined therapy with salmeterol and fluticasone as initial maintenance therapy in asthma. Respir Med (2007) 0.77
Pulmonary arterial remodeling in chronic obstructive pulmonary disease is lobe dependent. Pulm Circ (2013) 0.77
Obliterative bronchiolitis complicating bone marrow transplantation. Semin Respir Crit Care Med (2003) 0.77
Long-term outcomes of cadaveric lobar lung transplantation: helping to maximize resources. J Heart Lung Transplant (2009) 0.77
The implications of pulmonary embolism in a multiorgan donor for subsequent pulmonary, renal, and cardiac transplantation. J Heart Lung Transplant (2008) 0.76
Longitudinal comparisons of lymphocytes and subtypes between airway wall and bronchoalveolar lavage after human lung transplantation. Transplantation (2005) 0.76
Definitions of warm ischemic time when using controlled donation after cardiac death lung donors. Transplantation (2008) 0.75
Paediatric lobar lung transplantation: addressing the paucity of donor organs. Med J Aust (2008) 0.75
Is there a role for routine surveillance endotracheal aspirate cultures in the treatment of BAL-confirmed ventilator-associated pneumonia? Chest (2005) 0.75
Solving post-lung transplantation BOS: small steps and pitfalls. Am J Transplant (2005) 0.75
Inhaled corticosteroids and fracture risk: having our cake and eating it too. Chest (2005) 0.75
Lungs don't grow on trees: the ethics of increasing organ donation rates for transplantation and their relevance to the Asia-Pacific region. Respirology (2007) 0.75
Microangiopathic haemolytic anaemia and thrombocytopenia following lung volume reduction surgery in a single lung transplant recipient on maintenance tacrolimus (FK506) therapy. Respirology (2003) 0.75
Tracheobronchial involvement as a sole manifestation of relapsing polychondritis. J Bronchology Interv Pulmonol (2010) 0.75
Third-time lung transplant using extended criteria lungs. Ann Thorac Surg (2007) 0.75
University Health Network's chart completion project: engaging physicians. Healthc Q (2011) 0.75
Overview of sotrastaurin clinical pharmacokinetics. Ther Drug Monit (2010) 0.75
An unexpectedly high prevalence of undiagnosed diabetes in patients awaiting lung transplantation. J Heart Lung Transplant (2013) 0.75
Donor history of asthma is not a contraindication to lung transplantation: 12-year single-center experience. J Heart Lung Transplant (2004) 0.75
The Alfred Hospital Lung Transplant Experience. Clin Transpl (2014) 0.75
Hemophagocytic syndrome: a rare but specific complication of lung transplantation. J Thorac Cardiovasc Surg (2010) 0.75
Should lung transplant recipients routinely perform airway clearance techniques? A randomized trial. Respirology (2008) 0.75
Blinded and unblinded internal pilot study designs for clinical trials with count data. Biom J (2013) 0.75
Optimal design of clinical trials with biologics using dose-time-response models. Stat Med (2014) 0.75
Lung recruitment manoeuvres should be considered when assessing suitability for lung donation. Crit Care Resusc (2012) 0.75
Muddying the water for a clear diagnosis. J Bronchology Interv Pulmonol (2015) 0.75
The impact of period effects on dose level contrasts in alternating cross-over designs for first-time-in-human studies. Pharm Stat (2011) 0.75
Poor Glycemic Control is Associated with Decreased Survival in Lung Transplant Recipients. Transplantation (2016) 0.75
Designing a non-inferiority study in kidney transplantation: a case study. Pharm Stat (2011) 0.75